Engineered chimeric antigen receptor (CAR) immune cells successfully treat lymphomas; however, they are less efficient in targeting and eliminating solid tumors. Trafficking and ensuring their survival in the tumor microenvironment until all cancer cells are eliminated remains a challenge. In this webinar, experts will discuss advances that bring CAR therapy for solid tumors one step closer to reality.
Topics to be covered
Speaker Information:
Tamara Laskowski, PhD
Scientific Project Director
CAR NK Program, Adoptive Cell Therapy Platform
Department of Stem Cell Transplantation and Cellular Therapy
MD Anderson Cancer Center
Maik Luu, PhD
Project Principal Investigator
University Hospital Würzburg
Scientific Project Manager
T²EVOLVE
Drug Discovery News
1000 N West Street | Wilmington | Delaware | 19801 | US
Email: privacy@drugdiscoverynews.com
© 2021 Old River Publications LLC. All rights reserved
Drug Discovery News needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy